At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
oral azacitidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted May 3, 2013·Updated Oct 4, 2022
In Brief
A Phase 2 clinical trial evaluating oral azacitidine and Observation for Pancreatic Cancer. Completed, enrolled 49 participants across 4 sites.
Detailed Summary
To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as compared to observation after completion of adjuvant therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartJan 2014
Primary CompletionApr 2021
TodayJul 2026
First PostedMay 3, 2013
Enrollment StartJan 10, 2014
Primary CompletionApr 9, 2021
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 13.2 years ago
Interventions
oral azacitidinedrug
Observationother